Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Short term Debt (2019 - 2025)

Vivos Therapeutics' Short term Debt history spans 4 years, with the latest figure at $8.4 million for Q4 2025.

  • Quarterly results put Short term Debt at $8.4 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $8.4 million (changed N/A YoY), and the annual figure for FY2025 was $8.4 million, changed.
  • Short term Debt for Q4 2025 was $8.4 million at Vivos Therapeutics, up from $339000.0 in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $8.4 million in Q4 2025 to a low of $157000.0 in Q2 2025.